QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
QQQ   348.82 (-1.70%)
AAPL   177.82 (-0.78%)
MSFT   323.38 (-3.09%)
META   263.60 (-2.77%)
GOOGL   122.50 (-3.78%)
AMZN   121.23 (-4.25%)
TSLA   224.57 (+1.47%)
NVDA   374.75 (-3.05%)
NIO   7.76 (-1.52%)
BABA   85.29 (-1.63%)
AMD   117.83 (-5.15%)
T   16.09 (+2.68%)
F   13.59 (+5.11%)
MU   67.06 (-0.71%)
CGC   0.72 (-2.69%)
GE   106.08 (+0.59%)
DIS   92.53 (+0.40%)
AMC   4.73 (+1.94%)
PFE   38.89 (+1.36%)
PYPL   64.04 (-1.51%)
NFLX   399.77 (+0.12%)
NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News

$0.87
-0.02 (-2.24%)
(As of 06/7/2023 ET)
Compare
Today's Range
$0.82
▼
$0.94
50-Day Range
$0.72
▼
$1.03
52-Week Range
$0.72
▼
$2.12
Volume
309,057 shs
Average Volume
556,033 shs
Market Capitalization
$71.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Pieris Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
-0.14mentions of Pieris Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$8,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.67) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.94 out of 5 stars

Medical Sector

582nd out of 981 stocks

Pharmaceutical Preparations Industry

267th out of 462 stocks

See Top Rated MarketRank™ Stocks Here

PIRS stock logo

About Pieris Pharmaceuticals (NASDAQ:PIRS) Stock

Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin based drug candidate, elarekibep used for the treatment of asthma; and PRS-220, an oral inhaled Anticalin protein targeting connective tissue growth factor for the treatment of idiopathic pulmonary fibrosis. The company also develops PRS-344/S09501 2that consists of a PD-L1-targeting antibody and 4-1BB-targeting Anticalin proteins. It has a license and collaboration agreement with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seagen Inc.; and license agreements with Technical University of Munich and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts.

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

June 2, 2023 | finanznachrichten.de
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
June 2, 2023 | finance.yahoo.com
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
June 7, 2023 | MarketBeat Internal (Ad)
Save $200 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.
May 22, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
May 21, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Announces Presentation of Promising Preclinical Data for PRS-220 at ATS 2023 International Conference
May 17, 2023 | americanbankingnews.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) to Post Q2 2023 Earnings of ($0.16) Per Share, William Blair Forecasts
May 15, 2023 | finance.yahoo.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Analysts Just Cut Their EPS Forecasts Substantially
May 12, 2023 | seekingalpha.com
Pieris Pharmaceuticals GAAP EPS of -$0.18 misses by $0.04, revenue of $1.94M misses by $4.57M
June 7, 2023 | MarketBeat Internal (Ad)
Save $200 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.
May 11, 2023 | finance.yahoo.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q1 2023 Earnings Call Transcript
May 10, 2023 | msn.com
Recap: Pieris Pharmaceuticals Q1 Earnings
May 10, 2023 | finanznachrichten.de
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
May 10, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
May 9, 2023 | msn.com
Preview: Pieris Pharmaceuticals's Earnings
May 8, 2023 | americanbankingnews.com
Pieris Pharmaceuticals (PIRS) to Release Quarterly Earnings on Tuesday
May 5, 2023 | finance.yahoo.com
Pieris Pharmaceuticals, Inc.'s (NASDAQ:PIRS) Shares Lagging The Industry But So Is The Business
May 4, 2023 | finanznachrichten.de
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep
May 4, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
May 2, 2023 | finance.yahoo.com
Pieris Pharmaceuticals to Host First Quarter 2023 Investor Call and Provide Corporate Update on May 10, 2023
April 17, 2023 | finanznachrichten.de
Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa At 2023 AACR Annual Meeting
April 17, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
April 5, 2023 | americanbankingnews.com
William Blair Comments on Pieris Pharmaceuticals, Inc.'s Q1 2023 Earnings (NASDAQ:PIRS)
April 4, 2023 | americanbankingnews.com
Pieris Pharmaceuticals, Inc. Forecasted to Post Q1 2023 Earnings of ($0.19) Per Share (NASDAQ:PIRS)
April 2, 2023 | americanbankingnews.com
Equities Analysts Set Expectations for Pieris Pharmaceuticals, Inc.'s Q1 2024 Earnings (NASDAQ:PIRS)
April 1, 2023 | finance.yahoo.com
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Q4 2022 Earnings Call Transcript
March 31, 2023 | finance.yahoo.com
Pieris Pharmaceuticals Full Year 2022 Earnings: US$0.45 loss per share (vs US$0.71 loss in FY 2021)
March 31, 2023 | americanbankingnews.com
Jefferies Financial Group Comments on Pieris Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:PIRS)
See More Headlines

PIRS Price History

PIRS Company Calendar

Last Earnings
3/29/2023
Today
6/07/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PIRS
CUSIP
N/A
CIK
1583648
Web
www.pieris.com
Phone
(857) 246-8998
Fax
49-8161-141-1444
Employees
127
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-33,280,000.00
Net Margins
-245.45%
Pretax Margin
-245.45%
Return on Equity
-133.94%
Return on Assets
-42.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.41
Quick Ratio
1.41

Sales & Book Value

Annual Sales
$25.90 million
Price / Sales
2.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.38 per share
Price / Book
2.29

Miscellaneous

Outstanding Shares
82,020,000
Free Float
74,728,000
Market Cap
$71.51 million
Optionable
Optionable
Beta
1.08

Key Executives

  • Mr. Stephen S. Yoder J.D. (Age 47)
    CEO, Pres & Director
    Comp: $774.72k
  • Mr. Thomas Bures (Age 49)
    Sr. VP & CFO
    Comp: $499.38k
  • Mr. Ahmed S. Mousa J.D. (Age 38)
    Sr. VP, Chief Bus. Officer, Gen. Counsel & Corp. Sec.
    Comp: $519.78k
  • Dr. Hitto Kaufmann Ph.D. (Age 52)
    Sr. VP & Chief Scientific Officer
  • Maria Kelman
    Exec. Director of Investor Relations
  • Mr. Frank Vollmering
    VP of HR
  • Dr. Shane Olwill Ph.D. (Age 47)
    Sr. VP & Chief Devel. Officer
  • Mr. Prompong Chaikul (Age 36)
    Chief Supply Chain Officer
  • Dr. Florian Witte Ph.D.
    VP and Head of Alliance Management & Early Project Leadership

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













PIRS Stock - Frequently Asked Questions

How have PIRS shares performed in 2023?

Pieris Pharmaceuticals' stock was trading at $1.04 on January 1st, 2023. Since then, PIRS shares have decreased by 16.2% and is now trading at $0.8718.
View the best growth stocks for 2023 here.

When is Pieris Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PIRS earnings forecast.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) issued its earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.02. The biotechnology company earned $5.85 million during the quarter, compared to the consensus estimate of $6.51 million. Pieris Pharmaceuticals had a negative net margin of 245.45% and a negative trailing twelve-month return on equity of 133.94%.

What other stocks do shareholders of Pieris Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pieris Pharmaceuticals investors own include Verastem (VSTM), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Dynavax Technologies (DVAX), Sangamo Therapeutics (SGMO), Allena Pharmaceuticals (ALNA) and Anavex Life Sciences (AVXL).

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (1.63%), Platinum Investment Management Ltd. (1.31%), Acadian Asset Management LLC (0.85%), Renaissance Technologies LLC (0.52%), Candriam S.C.A. (0.47%) and Affinity Asset Advisors LLC (0.37%). Insiders that own company stock include Aquilo Capital Management, Llc, Christopher P Kiritsy, Shane Olwill and Tim Demuth.
View institutional ownership trends.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $0.87.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a market capitalization of $71.51 million and generates $25.90 million in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

The company employs 127 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The official website for the company is www.pieris.com. The biotechnology company can be reached via phone at (857) 246-8998, via email at kelman@pieris.com, or via fax at 49-8161-141-1444.

This page (NASDAQ:PIRS) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -